In:
Future Oncology, Future Medicine Ltd, Vol. 18, No. 27 ( 2022-09), p. 2999-3009
Abstract:
Tweetable abstract New #OpenAccess phase III #clinical trial protocol comparing ropeginterferon alfa-2b to anagrelide for second-line treatment in ET and includes the history of #interferon use in myeloproliferative neoplasms.
Type of Medium:
Online Resource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/fon-2022-0596
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2022
Permalink